ABVC BioPharma (ABVC) 10-K2023 FY Annual report

Filed: 13 Mar 24, 5:14pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AIBL, AiBtl, authoritative, awaiting, batch, Carbon, Chengdu, circumstance, cooperation, counterparty, cyber, cybersecurity, decentralization, decentralized, Delinquent, disable, DNA, estate, exact, Fellow, fraudulent, GAP, guard, Hua, Hui, hurt, Hybridization, inducement, insider, interoperability, invasion, invoiced, Ji, Leshan, Lian, living, metric, MNPI, nonmonetary, nonpublic, NTNU, Nucleobase, nutritional, outlined, parcel, Patil, Platinum, privacy, Pune, ready, real, rebuilding, resale, reset, Russman, sabotage, Sichuan, Summary, threatened, TS, Tsing, Tuan, unaudited, unbilled, uncollectible, usage, Uttam, waiting, waive, waiver, Workshop, Xinnovation, Xu, Zhewei, Zhong, Zhonghui

Removed: abandoned, accredited, acquirer, Adventure, Aid, Albany, Amkey, AMRI, Anatomy, AsiaGene, AsianGene, AU, autoimmunity, bearing, Bioscience, Bulletin, cancel, cancelled, categorized, Chihliang, Ching, chronic, COD, Cold, Comp, Concept, consent, consolidation, consummation, continuously, conveyance, designation, designee, domestically, earliest, Eastern, enactment, entry, EP, EPS, evidencing, evolving, explore, forgiven, Formosa, fractionalized, France, Frasergen, frequency, gas, gather, Genomic, Germany, Guoliang, Hampshire, Hsuan, hyaluronic, Hyperactive, incomplete, inflammation, integrate, inv, Italy, Jinwei, Kimho, Kingdom, KR, Kuo, LBG, LifeCode, Lin, Liu, load, location, LOI, magnitude, Maryland, Molecular, mother, movement, mutually, NCI, NIH, nonrecurring, nonrefundable, nutraceutical, oil, Organismal, oxidized, Parent, Paycheck, PCT, Ping, POC, PPP, precaution, Proof, provisional, pursuing, rank, ratio, recapitalization, recast, released, reliance, relief, represented, retainer, role, rolling, round, SAB, SBA, shape, Shen, signal, silicone, Spain, speed, Spring, stream, stronger, subscription, surrender, Switzerland, TaiGen, trajectory, translational, treating, TrimGen, Trust, TW, twenty, Tyan, Union, unsecured, USA, Utah, Veteran, ViewTrade, visualisation, Wei, West, winding, Wuhan, Yingfei, York, Yu, ZL

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ABVC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies, in his capacity as an officer of ABVC BioPharma, Inc. (the “Company”), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)

The Annual Report of the Company on Form 10-K for the fiscal year ended December 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 13, 2024

/s/ Uttam Patil
Uttam Patil
Chief Executive Officer (Principal Executive Officer)

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of a separate disclosure document.